Last reviewed · How we verify
TOOKAD VTP
TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis.
TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis. Used for Localized prostate cancer (intermediate and high-risk disease).
At a glance
| Generic name | TOOKAD VTP |
|---|---|
| Sponsor | Steba Biotech S.A. |
| Drug class | Photodynamic therapy agent |
| Target | Vascular endothelial cells (non-receptor mediated phototoxicity) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
TOOKAD (padeliporfin) is a lipophilic photosensitizer that localizes in the vasculature of tumors. Upon activation by 763 nm laser light, it generates singlet oxygen and reactive oxygen species that cause immediate vascular thrombosis and tumor ischemia, leading to rapid necrosis of the treated tissue. The VTP (vascular-targeted photodynamic therapy) approach selectively targets tumor blood vessels rather than tumor cells directly.
Approved indications
- Localized prostate cancer (intermediate and high-risk disease)
Common side effects
- Urinary retention
- Dysuria
- Urinary tract infection
- Perineal pain
- Photosensitivity reactions
Key clinical trials
- ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (PHASE3)
- Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. (PHASE2)
- Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer (PHASE1, PHASE2)
- Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer (PHASE4)
- European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
- Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer (PHASE3)
- Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PHASE3)
- Vascular Targeted Photodynamic Therapy T1a Renal Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOOKAD VTP CI brief — competitive landscape report
- TOOKAD VTP updates RSS · CI watch RSS
- Steba Biotech S.A. portfolio CI